1. Home
  2. IPM vs INKT Comparison

IPM vs INKT Comparison

Compare IPM & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPM
  • INKT
  • Stock Information
  • Founded
  • IPM 2005
  • INKT 2017
  • Country
  • IPM United States
  • INKT United States
  • Employees
  • IPM N/A
  • INKT N/A
  • Industry
  • IPM
  • INKT Medicinal Chemicals and Botanical Products
  • Sector
  • IPM
  • INKT Health Care
  • Exchange
  • IPM NYSE
  • INKT Nasdaq
  • Market Cap
  • IPM 27.9M
  • INKT 31.2M
  • IPO Year
  • IPM N/A
  • INKT 2021
  • Fundamental
  • Price
  • IPM $2.10
  • INKT $7.10
  • Analyst Decision
  • IPM Strong Buy
  • INKT Strong Buy
  • Analyst Count
  • IPM 1
  • INKT 2
  • Target Price
  • IPM $6.00
  • INKT $37.50
  • AVG Volume (30 Days)
  • IPM 90.4K
  • INKT 5.5K
  • Earning Date
  • IPM 05-14-2025
  • INKT 05-15-2025
  • Dividend Yield
  • IPM N/A
  • INKT N/A
  • EPS Growth
  • IPM N/A
  • INKT N/A
  • EPS
  • IPM N/A
  • INKT N/A
  • Revenue
  • IPM $6,344,746.00
  • INKT N/A
  • Revenue This Year
  • IPM $1,957.49
  • INKT N/A
  • Revenue Next Year
  • IPM $17.96
  • INKT N/A
  • P/E Ratio
  • IPM N/A
  • INKT N/A
  • Revenue Growth
  • IPM 14.16
  • INKT N/A
  • 52 Week Low
  • IPM $1.52
  • INKT $4.56
  • 52 Week High
  • IPM $5.50
  • INKT $13.79
  • Technical
  • Relative Strength Index (RSI)
  • IPM N/A
  • INKT 45.82
  • Support Level
  • IPM N/A
  • INKT $6.89
  • Resistance Level
  • IPM N/A
  • INKT $7.25
  • Average True Range (ATR)
  • IPM 0.00
  • INKT 0.35
  • MACD
  • IPM 0.00
  • INKT 0.01
  • Stochastic Oscillator
  • IPM 0.00
  • INKT 32.66

About IPM INTELLIGENT PROTECTION MANAGEMENT

Intelligent Protection Management Corp is a communications software innovator that powers multimedia social applications.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Share on Social Networks: